|Day Low/High||11.10 / 11.45|
|52 Wk Low/High||6.25 / 13.76|
AbbVie, Teva and Zimmer Biomet posted solid quarters and are upbeat about the road ahead.
Reports of merger talks have been confirmed, and we believe the two pharma giants would both benefit from the deal.
After flying high most of the year, the biopharma company is back on my radar.
Before you sell them, ask yourself at what multiple you sell.
I'll continue to add to Amgen, Teva and AbbVie incrementally as recent selloffs seem unwarranted.
Management team and acquisitions help make pharma company a buy.
Sometimes it pays to follow the leader. I am going to piggy back the call buyers and buy at-the-money calls in Teva Pharmaceutical.
Investors are most excited about Bluebird Bio (BLUE) and Pacira Pharmaceuticals (PCRX), according to Wedbush Securities, which is holding its annual healthcare investment conference in New York.
Drugmaker Allergan is putting off issuing guidance for future quarters following the company's announcement last week that it's selling its generic drug business to Teva Pharmaceuticals.
Jim Cramer, portfolio manager of Action Alerts PLUS, and research director Jack Mohr sat down to talk about their ‘favorite company in the portfolio:’ Allergan.
There is building consensus around a September rate hike.
I'm happy as always to be standing in for Doug Kass on the Daily Diary. Premarket futures are currently pointing to a slight opening rise. Let's see if we can build on yesterday's rally after previously seeing five straight declining sessions. Over...
In Tuesday’s Analysts' Actions, Wall Street firms review Teva Pharmaceutical Industries (TEVA), Baidu (BIDU), and Yelp (YELP).
Pharmaceutical giant Mylan (MYL) was the worst performing stock in the S&P 500 on Monday, making it TheStreet's Move of the Day.
Allergan (AGN) was the best performer on the S&P 500 Monday after Teva Pharmaceuticals (TEVA) agreed to buy its generic-drug business for more than $40 billion.
Jim Cramer is watching Twitter (TWTR) as the social media giant releases earnings for its second quarter on Tuesday, July 28th after the market’s closing bell.
And we are raising our price target on AGN.
U.S.-listed Chinese stocks were under pressure after China's stock market fell at the fastest pace since 2007 on Monday.
Two tech companies in Jim Cramer's charitable trust report as well.
Pharmaceutical firm's chart shows a likely move to the upside.
TEVA is a long candidate after a close in upper-candle range above the channel top.
Deal flow has been massive in the first half of 2015 from healthcare to technology to insurance.
They've done well considering market had a slightly negative month.
More names, including some surprises, showing up on bearish scans.